Literature DB >> 11374797

Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease.

P Surowiak1, P Dziegiel, M Zabel, R Matkowski, J Kornafel.   

Abstract

The pS2 protein belongs to the so called estrogen-dependent proteins, which appear in cells as a result of estrogen stimulation. The present study was aimed at determining prognostic value of estrogen receptor (ER) and pS2 protein expression in mammary cancer cells. The immunocytochemical reactions were performed in paraffin sections of tissue samples from 62 patients with ductal mammary carcinoma using monoclonal antibodies against ER and pS2. The analysis included also survival time of the patients, determined during the five-year observations. The studies documented a correlation between survival time and the level of ER expression (p=0.014) and absence of correlations between survival time and pS2 expression (p=0.55). The results indicate that evaluation of ER expression in mammary cancer cells may assist in defining prognosis of the patients while parallel estimation of pS2 expression in the cells is useless in this respect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374797

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  2 in total

1.  Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers.

Authors:  P Surowiak; V Materna; B Györffy; R Matkowski; A Wojnar; A Maciejczyk; P Paluchowski; P Dziegiel; M Pudełko; J Kornafel; M Dietel; G Kristiansen; M Zabel; H Lage
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640

2.  ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up.

Authors:  Agnieszka Halon; Piotr Donizy; Pawel Surowiak; Rafal Matkowski
Journal:  Cell Oncol (Dordr)       Date:  2013-02-19       Impact factor: 6.730

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.